Quantcast
Last updated on April 23, 2014 at 12:54 EDT

Latest Granisetron Stories

2013-07-23 08:31:42

CHARLESTON, S.C., July 23, 2013 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the completion of its scheduled Pre-IND meeting with the U.S Food and Drug Administration (FDA) for the proposed Investigational New Drug, CL-H1T, as a novel...

2012-05-28 02:20:47

CAMBRIDGE, England, May 28, 2012 /PRNewswire/ -- Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients at moderate-to-high risk of suffering PONV. Vomiting and especially nausea remain a major problem for patients after surgical operations, despite the...

2012-01-27 09:32:00

SAN DIEGO, CA, and CALIFON, NJ, Jan. 27, 2012 /PRNewswire/ - Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI http://www.apricusbio.com) and PediatRx, Inc. ("PediatRx") (OTCBB: PEDX) (http://www.pediatrx.com) announced today the execution of a binding term sheet for (1) the U.S. co-promotion of, and sale of non-U.S. rights to PediatRx's GRANISOL (granisetron HCI) oral solution, the only FDA-approved, oral, ready-to-use liquid solution of granisetron and (2) the...

2011-07-06 08:35:00

CALIFON, NJ, July 6, 2011 /PRNewswire/ - PediatRx, Inc. ("PediatRx") (OTCBB: PEDX), a hospital specialty company with a current focus on oncology supportive care, has secured all of the state licenses currently necessary to sell GRANISOL directly to wholesalers and distributors in the U.S.  Sales are now being fulfilled directly by Integrated Commercialization Solutions, Inc. ("ICS"), one of the country's largest third-party logistics providers for pharmaceutical products. ICS is...

2011-06-08 05:00:00

LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48...

2011-06-01 08:00:00

GRANISOL's co-pay program covers patient out-of-pocket costs for non-Medicare and non-Medicaid patients CALIFON, NJ, June 1, 2011 /PRNewswire/ - PediatRx, Inc. (OTCBB: PEDX), a hospital specialty company with a focus on oncology supportive care, recently polled a representative sample of approximately 70 US oncologists and other physician specialists and found that the majority (78%) viewed "no patient out-of-pocket costs" as a motivating factor for prescribing GRANISOL. GRANISOL...

2011-05-05 15:19:00

Oncologists report that patient out-of-pocket costs can impact form of dosage CALIFON, NJ, May 5 /PRNewswire/ - PediatRx, Inc. (OTCBB: PEDX), a hospital specialty company with a focus on oncology supportive care, released poll data today showing that 98% of physician respondents said at least some of their patients are using co-pay assistance programs for cancer-related prescription medications. The poll was conducted by PediatRx in collaboration with Sermo and all respondents were...

2011-04-25 07:00:00

Fear of nausea a significant issue and often not discussed with healthcare providers CALIFON, NJ, April 25 /PRNewswire/ - PediatRx, Inc. (OTCBB: PEDX) today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects.(1-9 )The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous...

2011-04-13 09:29:00

CALIFON, N.J., April 13, 2011 /PRNewswire/ -- PediatRx, Inc. (OTCBB: PEDX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) recently notified state Medicaid agencies to include PediatRx's GRANISOL, NDC 52547-0801-30, in their list of reimbursed products. CMS funds the Medicaid and State Children Health Insurance Programs jointly with state governments. These programs provide health insurance, including prescription drug coverage, to over 40 million low-income...

2011-02-01 08:00:00

Patients could instantly save up to $200 off the cost of their co-pay CALIFON, NJ, Feb. 1 /PRNewswire/ - PediatRx Inc. (OTCBB: PEDX) is pleased to announce the launch of a co-pay assistance program* to support use of  GRANISOL. This unique program allows patients to instantly save up to $200 off their co-pay each time they are prescribed GRANISOL. There are various ways in which the program can be accessed. A mobile phone texting version allows patients and caregivers to text...